1.3.1. Treating disease, including developing regenerative medicine

There is a need to support the improvement of cross-cutting support technologies for drugs, biotherapies, vaccines and other therapeutic approaches, including transplantation, surgery, gene and cell therapy and nuclear medicine; to increase success in the drug and vaccine development process (including alternative methods to replace classical safety and effectiveness testing, e.g. the development of new methods); to develop regenerative medicine approaches, including approaches based on stem cells; to develop new biopharmaceuticals, including therapeutic vaccines; to develop improved medical and assistive devices and systems; to improve palliative therapies; to maintain and enhance the ability to combat disease and undertake medical interventions that depend on the availability of effective and safe antimicrobial drugs; and to develop comprehensive approaches to treat co-morbidities at all ages and avoid poly-pharmacy. These improvements will facilitate the development of new, more efficient, effective, sustainable and personalised treatments for disease and for the management of disability and frailty, including advanced therapies and cellular therapies for the treatment of chronic diseases.

← 1.3. Treating and managing disease · All articles · anx_I__cpt_1__cpt_6__cpt_1__cpt_3__cpt_1__text_1 →

Source: EUR-Lex (Cellar) · retrieved 2026-11-04 · Text as adopted (Official Journal); later amendments are not incorporated in this text.